Evidence map›Paper›PMID 21850662›Full record

ArticleAmerican journal of hematology2011

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Tariq I Mughal, Jerald P Radich, Richard A Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli, Ayalew Tefferi

Abstract readConference Proceedings
In one paragraph

Article in American journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tariq I MughalUniversity of Colorado School of Medicine, Denver, CO, USA. tmughal911@hotmail.com
Jerald P Radich
Richard A Van Etten
Alfonso Quintás-Cardama
Tomasz Skorski
Farhad Ravandi
Daniel J DeAngelo
Carlo Gambacorti-Passerini
Giovanni Martinelli
Ayalew Tefferi

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICER01CA090576 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI VAN ETTEN, RICHARD A. · 2001 to 2021
$5.9M
Molecular Pathogenesis & Therapy of JAK2 V617F-induced Myeloproliferative DiseaseR01HL089747 · NHLBI · TUFTS MEDICAL CENTER · PI VAN ETTEN, RICHARD A. · 2008 to 2012
$2.0M
NCI NIH HHS R01 CA090576NHLBI NIH HHS R01 HL089747
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsDrug MonitoringDrug Resistance, NeoplasmGenomic InstabilityHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeAntineoplastic Agents

Identifiers

PMID21850662
PMCPMC3485684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.